Press release: Neurizon's NUZ-001 Reduces Aggregation of Key …
Nov 19, 2024 · Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications.
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
20 hours ago · IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 The IND is a comprehensive dossier of information ...
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease …
Nov 19, 2024 · These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of...
EMA recommends NUZ-001 for orphan designation in Europe
Nov 19, 2024 · The European Medicines Agency (EMA) has recommended that monepantel, now named NUZ-001, be granted orphan medicinal product designation to treat amyotrophic lateral sclerosis (ALS). The positive opinion will be reviewed by the European Commission, which is expected to issue a final decision in December.
In big news week Neurizon secures key orphan status for motor …
5 hours ago · In other good news this week, NUZ also reported a positive interim eight-month update on its ongoing 12-month open-label extension (OLE) study of NUZ-001 in patients with ALS.
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease
Nov 20, 2024 · NUZ-001 and NUZ-001 Sulfone rescued the electrical activity of TDP-43 M337V Motor Neurons, by increasing bursting and network burst activity, and reducing inter-burst intervals to wild type Motor Neuron activity levels.
Neurizon's Lead Drug NUZ-001 Shows Promise for ALS Treatment
Nov 19, 2024 · Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) announces significant findings from recent preclinical studies involving their leading drug candidate, NUZ-001. These encouraging results are centered around the compound's ability to reduce the aggregation of TAR DNA-binding protein 43 (TDP-43), a critical factor in the pathology of Amyotrophic ...
Positive interim study results for Neurizon’s motor neurone …
2 days ago · Neurizon Therapeutics (ASX: NUZ), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, said the latest results confirm NUZ-001’s long-term safety and ...
Neurizon Therapeutics Receives Positive Opinion on Orphan …
Nov 11, 2024 · Neurizon is advancing NUZ-001 through a Phase 2/3 clinical study as part of the HEALEY ALS Platform Trial, with patient enrolment expected to commence in early H1 CY2025. Our protocol regimen has...
Neurizon Therapeutics says candidate reduces aggregation of key …
Nov 19, 2024 · Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001. Amyotrophic Lateral Sclerosis (ALS) is a fatal type of motor neuron disease. It causes progressive degeneration of …
- Some results have been removed